1.Experimental study on microencapsulated NGF expressing NIH3T3 cells on repair of peripheral nerve defect in rats
Jingguo ZHAO ; Ju ZHANG ; Fengtong GAO
Journal of Jilin University(Medicine Edition) 2006;0(02):-
Objective To investigate the effects of microencapsulated NGF expressing NIH3T3 cells on the repair of peripheral nerve defect in rats.Methods Thirty SD male rats with 10 mm defect of sciatic nerve were randomly divided into three groups(n=10).Group A: The nerve defect was bridged with heterogeneous nerve,the neural regeneration room was formed and filled with microencapsulated NGF expressing NIH3T3 cells.Group B: Autogenous nerve grafting was performed.Group C: The nerve defect was bridged with heterogeneous nerve,the neural regeneration room was formed and filled with microencapsulated NIH3T3 cells.The walking track analysis,electrophysiological and morphological observation were performed 12 weeks after operation.Results There were no significant differences of sciatic nerve function index,nerve concluctive velocity,histological changes of regenerative nerve,maturation degree of regenerative nerve fiber between group A and group B 4,8,12 weeks after operation;group A and B were surperior to group C(P
2.Long-term outcomes of intracavitary hyperthermia in combination with radiotherapy for locally advanced uterine cervical cancer
Qingsong PANG ; Ruiying LI ; Qiuling GAO ; Junquan YANG ; Fengtong LI ; Li ZHU ; Xue MEI ; Haipan WANG ; Ping WANG
Chinese Journal of Radiation Oncology 2008;17(6):454-457
Objective To evaluate the long-term clinical efficacy and toxicities of combined intracavitary hyperthermia and radiotherapy fur locally advanced uterine cervical cancer. Methods 310 patients with locally advanced uterine cervical cancer were assigned into intracavitary hyperthermia + radiotherapy group(TRT, 181 patients) and external-beam radiotherapy + traditional intracavitary radiation group (RT,129 patients). The external-beam radiotherapy were given with 60Co γ-my or 6-8 MV X-ray in traditional fractionation. In TRT group,radiotherapy was 40 Gy using the anterior-posterior pelvic fields and additional 20-25 Gy using the lateral fields. Hyperthermia was delivered by the 915 MHz microwave hyperthermia device within 15-60 min after external radiotherapy for 10-12 times(40 min each time,1-2 times per week). The temperature of tumor surface was 46-47℃. In the RT group, the external-beam radiotherapy of 40 Gy was delivered using the anterior-posterior pelvic fields. The intracavity radiotherapy of radium was delivered before 1989 ,with 50 mg radium in the vagina and 30 mg in uterine cavity for 24 hours ,weekly for 3 times to a total dose of 7200 mg·h. After 1989,intraeavity radiotherapy of 192Ir was delivered to a total dose of 30-36 Gy to point A in 5-6 Gy fractions,2 fractions per week. Results The 5-year survival of patients in TRT group and RT group was 67.4% versus 52.1% for stage Ⅱ disease (χ2=7.55,P=0.006), and 60.0% vemus32.3% forstage Ⅲ (χ2=7.06,P=0.007) . The 10-year survival was46.5% versus42.6% for stage Ⅱ (χ2=3.90,P=0.058), and 43.7% versus 20.6% for stage Ⅲ(χ2=17.28,P=0.000). Cox regression analysis showed that the tumor stage(P=0.023) and intracavitary hyperthermia( P=0.019) were prognostic factors. According to the RTOG criteria, the rate of mild to moderate late side effects of rectum and bladder in TRT and RT group was 17.7% and 33.1%, respectively (χ2=9.18, P=0.002). Rectovaginal fistula was developed in5 patients(3.9% ) in RT group and I patient (0.6%) in TRT group(χ2= 4.38,P=0.036). Conclusions The long-term survival of patients with stage Ⅲ uterine cervical cancer is better of TRT group than RT group. The TRT is well tolerated and the late toxicity rate is obviously low. It is necessary to carry out large randomized clinical trials to confirm these outcomes.
3.Preliminary clinical study on treatment of prostate cancer with Cyber-Knife
Hanjing GAO ; Zhen TAO ; Huanhuan WANG ; Fengtong LI ; Yang DONG ; Xuyao YU ; Jingsheng WANG ; Huaming CHEN ; Yongchun SONG ; Zhiyong YUAN
Chinese Journal of Radiological Medicine and Protection 2019;39(6):415-421
Objective To evaluate the safety and effectiveness of ultra-hypofractionated stereotactic body radiotherapy in the treatment of prostate cancer.Methods A total of 26 patients with prostate cancer treated with Cyber-Knife from May 2010 to May 2018 were analyzed retrospectively.The median age of the patients was 69 years old (range,57 to 87).Ultra-hypofractionated radiotherapy was delivered in five fractions of 7.0-7.5 Gy for a total dose of 35.0-37.5 Gy.Androgen deprivation therapy (ADT) was administered in combination with the Cyber-Knife.The primary endpoints were radiation toxicity,PSA-response,local control and symptom alleviation,while the secondary endpoints were progression-free survival and overall survival.Results No graded ≥ 3 acute and late radiation toxicities occurred during follow-up.The acute toxicity of Grades 1 and 2 was 38.4% and 19.2%,while the late toxicity of Grades 1 and 2 was 30.8% and 3.8%,respectively.At a median follow-up of 22.44 months,for patients with localized stage,PSA level was decreased significantly after radiotherapy (Z =2.900,2.794,2.510,2.090,P<0.05).However,there was no statistically significant difference for the metastatic group (P> 0.05).Conclusions Ultra-hypofractionated stereotactic body radiotherapy is a safe and effective treatment for patients with prostate cancer.